Akari Therapeutics PLC (AKTX) Sets New 52-Week Low at $3.43
Shares of Akari Therapeutics PLC (NASDAQ:AKTX) reached a new 52-week low during trading on Friday . The company traded as low as $3.43 and last traded at $3.43, with a volume of 12,493 shares traded. The stock had previously closed at $3.62.
A number of analysts have recently commented on the company. Chardan Capital reissued a “sell” rating and issued a $6.50 price objective on shares of Akari Therapeutics PLC in a research note on Tuesday, April 25th. William Blair downgraded Akari Therapeutics PLC from an “outperform” rating to a “market perform” rating in a research note on Friday, May 12th. Zacks Investment Research downgraded Akari Therapeutics PLC from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Finally, Canaccord Genuity reissued a “buy” rating and issued a $15.00 price objective (down previously from $33.00) on shares of Akari Therapeutics PLC in a research note on Monday, June 26th.
The company has a 50 day moving average price of $4.54 and a 200-day moving average price of $7.74. The stock’s market cap is $39.92 million.
A hedge fund recently bought a new stake in Akari Therapeutics PLC stock. Hikari Power Ltd purchased a new stake in Akari Therapeutics PLC (NASDAQ:AKTX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 60,012 shares of the biopharmaceutical company’s stock, valued at approximately $277,000. Hikari Power Ltd owned approximately 0.51% of Akari Therapeutics PLC as of its most recent filing with the SEC. Hedge funds and other institutional investors own 28.75% of the company’s stock.
About Akari Therapeutics PLC
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.